Novo Nordisk’s CagriSema achieved significant weight loss in phase 3 trials, though safety concerns may limit its edge over existing and pipeline rivals.
Latest Ratings for NVO
DateFirmActionFromTo Jan 2022LiberumDowngradesHoldSell Dec 2021JP MorganDowngradesOverweightNeutral Jan 2021Deutsche BankInitiates Coverage OnBuy